Qinghao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qinghao Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Changsheng Liu
Engineering Research Center for Biomedical Materials of the Ministry of Education, East China University of Science and Technology, Shanghai, 200237, PR China
1 shared publication Dandan Long
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China
1 shared publicationFuwei Zhu
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China
1 shared publication- Jing Wang
The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China
1 shared publication - Kai Dai
The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, People’s Republic of China
1 shared publication Shuang Zhang
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, PR China
1 shared publication
Latest Publications
- 6 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (1) , eadd1541
A BMP-2–triggered in vivo osteo-organoid for cell therapy
Cell therapies and regenerative medicine interventions require an adequate source of therapeutic cells. Here, we demonstrate that constructing in vivo osteo-organoids by implanting bone morphogenetic protein–2–loaded scaffolds into the internal muscle pocket near the femur of mice supports the growth and subsequent harvest of therapeutically useful cells including hematopoietic stem/progenitor cells (HSPCs), mesenchymal stem cells (MSCs), lymphocytes, and myeloid cells. Profiling of the in vivo osteo-organoid maturation process delineated three stages—fibroproliferation, osteochondral differentiation, and marrow generation—each of which entailed obvious changes in the organoid structure and cell type distribution. The MSCs harvested from the osteochondral differentiation stage mitigated carbon tetrachloride (CCl 4 )–induced chronic liver fibrosis in mice, while HSPCs and immune cells harvested during the marrow generation stage rapidly and effectively reconstituted the impaired peripheral and solid immune organs of irradiated mice. These findings demonstrate the therapeutic potentials of in vivo osteo-organoid–derived cells in cell therapies.
- 6 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (1) , eadd1541
A BMP-2–triggered in vivo osteo-organoid for cell therapy
Cell therapies and regenerative medicine interventions require an adequate source of therapeutic cells. Here, we demonstrate that constructing in vivo osteo-organoids by implanting bone morphogenetic protein–2–loaded scaffolds into the internal muscle pocket near the femur of mice supports the growth and subsequent harvest of therapeutically useful cells including hematopoietic stem/progenitor cells (HSPCs), mesenchymal stem cells (MSCs), lymphocytes, and myeloid cells. Profiling of the in vivo osteo-organoid maturation process delineated three stages—fibroproliferation, osteochondral differentiation, and marrow generation—each of which entailed obvious changes in the organoid structure and cell type distribution. The MSCs harvested from the osteochondral differentiation stage mitigated carbon tetrachloride (CCl 4 )–induced chronic liver fibrosis in mice, while HSPCs and immune cells harvested during the marrow generation stage rapidly and effectively reconstituted the impaired peripheral and solid immune organs of irradiated mice. These findings demonstrate the therapeutic potentials of in vivo osteo-organoid–derived cells in cell therapies.